DLL4 expression is a prognostic marker and may predict gemcitabine benefit in resected pancreatic cancer

被引：0
|
作者：
A Drouillard
F Puleo
J B Bachet
S Ouazzani
A Calomme
P Demetter
G Verset
J L Van Laethem
R Maréchal
机构：
[1] University Hospital of Dijon,Department of Gastroenterology and Digestive Oncology
[2] Digestive Cancer Registry of Burgundy,Department of Gastroenterology and Digestive Oncology
[3] INSERM U866,Department of Hepatogastroenterology
[4] University Hospital of Dijon,Department of Pathology
[5] Erasme Hospital,undefined
[6] Pitié Salpêtrière Hospital,undefined
[7] APHP,undefined
[8] Erasme Hospital,undefined
[9] Laboratory of Experimental Gastroenterology,undefined
[10] Université Libre de Bruxelles,undefined
来源：
British Journal of Cancer | 2016年 / 115卷
关键词：
DLL4; Notch1; Notch3; pancreatic cancer; biomarker; immunohistochemistry;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1245 / 1252
页数：7
相关论文
共 50 条
  • [21] Ca 125 is an independent prognostic marker in resected pancreatic cancer of the head of the pancreas
    Napoli, Niccolo
    Kauffmann, Emanuele F.
    Ginesini, Michael
    Lami, Lucrezia
    Lombardo, Carlo
    Vistoli, Fabio
    Campani, Daniela
    Boggi, Ugo
    UPDATES IN SURGERY, 2023, 75 (06) : 1481 - 1496
  • [22] Ca 125 is an independent prognostic marker in resected pancreatic cancer of the head of the pancreas
    Niccolò Napoli
    Emanuele F. Kauffmann
    Michael Ginesini
    Lucrezia Lami
    Carlo Lombardo
    Fabio Vistoli
    Daniela Campani
    Ugo Boggi
    Updates in Surgery, 2023, 75 : 1481 - 1496
  • [23] Notch and Delta-like 4 ligand (DLL4) expression in bevacizumabtreated colorectal cancer patients
    Negri, F. V.
    Bozzetti, C.
    Crafa, P.
    Lagrasta, C.
    Pedrazzi, G.
    Gardini, G.
    Tamagnini, I.
    Porzio, R.
    Tomasello, G.
    Ardizzoni, A.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S565 - S565
  • [24] Survivin expression is a prognostic marker in pancreatic cancer patients
    Kami, K
    Doi, R
    Koizumi, M
    Toyoda, E
    Mori, T
    Ito, D
    Fujimoto, K
    Wada, M
    Miyatake, SI
    Imamura, M
    SURGERY, 2004, 136 (02) : 443 - 448
  • [25] ANALYSIS OF THE RELATIONSHIP BETWEEN MIR-195 TARGETING DLL4 EXPRESSION IN COLORECTAL CANCER
    Li, Guosheng
    Huang, Fei
    Yang, Yunhong
    JOURNAL OF INVESTIGATIVE MEDICINE, 2023, 71 : 29 - 29
  • [26] The effect of TRPS1 expression on adjuvant gemcitabine efficacy in resected pancreatic cancer
    Guenther, M.
    Ormanns, S.
    ANNALS OF ONCOLOGY, 2024, 35 : S156 - S156
  • [27] IL17RB expression might predict prognosis and benefit from gemcitabine in patients with resectable pancreatic cancer
    Yao, Song
    Ji, Bin
    Chen-xia Jiang
    Zhi-ming Chen
    Ning-hua Yao
    Mukaida, Naofumi
    Huang, Hua
    PATHOLOGY RESEARCH AND PRACTICE, 2019, 215 (12)
  • [28] Evaluation of the prognostic role of aspirin and metformin in the ESPAC 4 randomised trial of adjuvant gemcitabine versus gemcitabine plus capecitabine in patients with resected pancreatic cancer
    Ponweera, Arachchige
    Robinson, Matthew
    Jackson, Richard
    Halloran, Chris
    Palmer, Dan
    Hackert, Thilo
    Costello, Eithne
    Greenhalf, Bill
    Buechler, Markus
    Neoptolemos, John
    Ghaneh, Paula
    BRITISH JOURNAL OF SURGERY, 2022, 109
  • [29] Cancer Derived Immunoglobulin G as a Prognostic Marker in Patients with Resected Pancreatic Ductal Adenocarcinoma
    Cui, Ming
    Liao, Quan
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2019, 229 (04) : E142 - E142
  • [30] Nardilysin in resected tissue may predict a post-operative prognosis of pancreatic cancer
    Yasukawa, Daiki
    Miyake, Toru
    Tani, Masaji
    Nishi, Eiichiro
    CANCER SCIENCE, 2021, 112 : 496 - 496
12345